Medtronic (NYSE:MDT) touted data today from a two-year study of its In.Pact Admiral drug-coated balloon in patients with peripheral artery disease in Japan, as well as the results from a critical limb ischemia subgroup analysis from its In.Pact Global trial.
The company’s In.Pact SFA Japan study enrolled 100 patients and randomized them to receive either the drug-coated balloon or plain balloon angioplasty.
Get the full story at our sister site, Drug Delivery Business News.
The post Medtronic’s In.Pact Admiral drug-coated balloon succeeds in two-year study, critical limb ischemia analysis appeared first on MassDevice.
from MassDevice http://ift.tt/2BFN9tM
Cap comentari:
Publica un comentari a l'entrada